141 related articles for article (PubMed ID: 26951750)
1. Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors.
Stauffer F; Cowan-Jacob SW; Scheufler C; Furet P
Bioorg Med Chem Lett; 2016 Apr; 26(8):2065-7. PubMed ID: 26951750
[TBL] [Abstract][Full Text] [Related]
2. Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.
Fairhurst RA; Marsilje TH; Stutz S; Boos A; Niklaus M; Chen B; Jiang S; Lu W; Furet P; McCarthy C; Stauffer F; Guagnano V; Vaupel A; Michellys PY; Schnell C; Jeay S
Bioorg Med Chem Lett; 2016 Apr; 26(8):2057-64. PubMed ID: 26951753
[TBL] [Abstract][Full Text] [Related]
3. Cyclopentyl-pyrimidine based analogues as novel and potent IGF-1R inhibitor.
Aware V; Gaikwad N; Chavan S; Manohar S; Bose J; Khanna S; B-Rao C; Dixit N; Singh KS; Damre A; Sharma R; Patil S; Roychowdhury A
Eur J Med Chem; 2015 Mar; 92():246-56. PubMed ID: 25559205
[TBL] [Abstract][Full Text] [Related]
4. Optimization of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine IGF-1R tyrosine kinase inhibitors towards JNK selectivity.
Chamberlain SD; Redman AM; Wilson JW; Deanda F; Shotwell JB; Gerding R; Lei H; Yang B; Stevens KL; Hassell AM; Shewchuk LM; Leesnitzer MA; Smith JL; Sabbatini P; Atkins C; Groy A; Rowand JL; Kumar R; Mook RA; Moorthy G; Patnaik S
Bioorg Med Chem Lett; 2009 Jan; 19(2):360-4. PubMed ID: 19071018
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 3,5-disubstituted-1H-pyrrolo[2,3-b]pyridines as potent inhibitors of the insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase.
Patnaik S; Stevens KL; Gerding R; Deanda F; Shotwell JB; Tang J; Hamajima T; Nakamura H; Leesnitzer MA; Hassell AM; Shewchuck LM; Kumar R; Lei H; Chamberlain SD
Bioorg Med Chem Lett; 2009 Jun; 19(11):3136-40. PubMed ID: 19394223
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth factor-1 receptor (IGF-1R) inhibitors.
Buchanan JL; Newcomb JR; Carney DP; Chaffee SC; Chai L; Cupples R; Epstein LF; Gallant P; Gu Y; Harmange JC; Hodge K; Houk BE; Huang X; Jona J; Joseph S; Jun HT; Kumar R; Li C; Lu J; Menges T; Morrison MJ; Novak PM; van der Plas S; Radinsky R; Rose PE; Sawant S; Sun JR; Surapaneni S; Turci SM; Xu K; Yanez E; Zhao H; Zhu X
Bioorg Med Chem Lett; 2011 Apr; 21(8):2394-9. PubMed ID: 21414779
[TBL] [Abstract][Full Text] [Related]
7. Optimization of a series of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidine inhibitors of IGF-1R: elimination of an acid-mediated decomposition pathway.
Chamberlain SD; Redman AM; Patnaik S; Brickhouse K; Chew YC; Deanda F; Gerding R; Lei H; Moorthy G; Patrick M; Stevens KL; Wilson JW; Brad Shotwell J
Bioorg Med Chem Lett; 2009 Jan; 19(2):373-7. PubMed ID: 19081716
[TBL] [Abstract][Full Text] [Related]
8. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a Potent, Selective, Orally Bioavailable, and Efficacious Novel 2-(Pyrazol-4-ylamino)-pyrimidine Inhibitor of the Insulin-like Growth Factor-1 Receptor (IGF-1R).
Degorce SL; Boyd S; Curwen JO; Ducray R; Halsall CT; Jones CD; Lach F; Lenz EM; Pass M; Pass S; Trigwell C
J Med Chem; 2016 May; 59(10):4859-66. PubMed ID: 27078757
[TBL] [Abstract][Full Text] [Related]
10. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.
Whitson BA; Jacobson BA; Frizelle S; Patel MR; Yee D; Maddaus MA; Kratzke RA
Ann Thorac Surg; 2006 Sep; 82(3):996-1001; discussion 1001-2. PubMed ID: 16928523
[TBL] [Abstract][Full Text] [Related]
11. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological activity of N
Kurup S; McAllister B; Liskova P; Mistry T; Fanizza A; Stanford D; Slawska J; Keller U; Hoellein A
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):74-84. PubMed ID: 29115879
[TBL] [Abstract][Full Text] [Related]
14. Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.
Bell IM; Stirdivant SM; Ahern J; Culberson JC; Darke PL; Dinsmore CJ; Drakas RA; Gallicchio SN; Graham SL; Heimbrook DC; Hall DL; Hua J; Kett NR; Kim AS; Kornienko M; Kuo LC; Munshi SK; Quigley AG; Reid JC; Trotter BW; Waxman LH; Williams TM; Zartman CB
Biochemistry; 2005 Jul; 44(27):9430-40. PubMed ID: 15996097
[TBL] [Abstract][Full Text] [Related]
15. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
[TBL] [Abstract][Full Text] [Related]
16. Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.
Bao XH; Takaoka M; Hao HF; Wang ZG; Fukazawa T; Yamatsuji T; Sakurama K; Sun DS; Nagasaka T; Fujiwara T; Naomoto Y
Anticancer Res; 2012 Jul; 32(7):2827-34. PubMed ID: 22753744
[TBL] [Abstract][Full Text] [Related]
17. Structure-guided development of covalent TAK1 inhibitors.
Tan L; Gurbani D; Weisberg EL; Hunter JC; Li L; Jones DS; Ficarro SB; Mowafy S; Tam CP; Rao S; Du G; Griffin JD; Sorger PK; Marto JA; Westover KD; Gray NS
Bioorg Med Chem; 2017 Feb; 25(3):838-846. PubMed ID: 28011204
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, biological evaluation and docking studies of new pyrrolo[2,3-d] pyrimidine derivatives as Src family-selective tyrosine kinase inhibitors.
Dincer S; Cetin KT; Onay-Besikci A; Ölgen S
J Enzyme Inhib Med Chem; 2013 Oct; 28(5):1080-7. PubMed ID: 22957720
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
[TBL] [Abstract][Full Text] [Related]
20. Discovery of 4,6-bis-anilino-1H-pyrrolo[2,3-d]pyrimidines: potent inhibitors of the IGF-1R receptor tyrosine kinase.
Chamberlain SD; Wilson JW; Deanda F; Patnaik S; Redman AM; Yang B; Shewchuk L; Sabbatini P; Leesnitzer MA; Groy A; Atkins C; Gerding R; Hassell AM; Lei H; Mook RA; Moorthy G; Rowand JL; Stevens KL; Kumar R; Shotwell JB
Bioorg Med Chem Lett; 2009 Jan; 19(2):469-73. PubMed ID: 19056263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
